Levetiracetam Injection
Product Images NDC 66298-0467

This is a description of Levetiracetam 190 mg in 0.54% Sodium Chloride Injection for intravenous infusion. It is to be used immediately after removal from the overwrap and infused over a 15-minute period. Each 100 mL contains Levetiracetam 1,500 mg, Sodium Chloride 540 mg, and Glacial Acetic Acid 7.5 mg, buffered at approximately pH 5.5. It should not be used in series connections, diluted further before use, and should only be used if the solution is clear. The usual adult dosage is mentioned in the package insert. The product should be stored at 20° to 25°C (68° to 77°F) and is a single-dose dual port bag. The closure is not made with natural rubber and is latex-free, non-PVC, and non-DEHP. It is manufactured by Fresenius Kabi and made in Norway.*

This is a description of Levetiracetam Y Eresenus solution in 0.54% Sodium Chloride manufactured in Lake Zurich, IL. Each bag contains 1,500 mg in 100 mL. It is made in Norway and must be stored at 20-25°C. The solution is for intravenous infusion only and should be discarded if leaks are found. Each box contains 24 single-dose bags. Be cautious when opening the container to maintain sterility.*

This is a description for Levetiracetam in 0.54% Sodium Chloride Injection with a concentration of 1,500 mg in 100 mL (15 mg per mL). It is for intravenous infusion only and available by prescription only. The provided identification numbers are 403111A and 01-79-12-003.*

This data shows the adverse reactions reported for individuals taking Levetiracetam compared to a placebo. The table lists various side effects and the percentage of individuals experiencing them under each treatment. Adverse reactions such as asthenia, somnolence, headache, infection, dizziness, and others are included in the comparison. It provides insight into the differences in reported side effects between the two treatments.*

This text displays a comparison of patient percentages across different treatment groups: Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day. It indicates that the patient groups receiving Levetiracetam at both dosage levels showed statistically significant differences compared to the placebo group. *

This is a description of a clinical trial or study comparing the drug Levetiracetam at a dose of 3,000 mg/day to a placebo in patients. The table shows different percentages related to the treatment and the number of patients. The results highlight a statistically significant difference between the Levetiracetam group (N = 180) and the placebo group (N = 104).*

This text appears to be a table showing percentages of patients in different treatment groups (Placebo and Levetiracetam) with associated values. The data includes percentages ranging from 0% to 100% for both groups. The mention of "statistically significant versus placebo" suggests that the comparison between the two groups is being highlighted for a specific outcome or variable.*

This is a comparison of the effectiveness of different doses of Levetiracetam (1,000 mg/day and 3,000 mg/day) versus a placebo in a sample of 95, 97, and 101 patients, respectively. The text includes percentages representing results for each group, with the statement that the differences are statistically significant.*